Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

37
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
37
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

71
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
71
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Bleeding risk assessment in patients with new-onset atrial fibrillation after CABG.

European heart journal. Cardiovascular pharmacotherapy·2026
Same author

Growth patterns in patients with congenital adrenal hyperplasia analyzed by the QEPS growth model.

Frontiers in endocrinology·2026
Same author

Bleeding risk assessment in patients with new-onset atrial fibrillation after coronary surgery: A proof-of-concept study.

European heart journal. Cardiovascular pharmacotherapy·2026
Same author

Sex Differences in Clinical Outcomes and Loss of Life Expectancy After Aortic Valve Surgery for Infective Endocarditis: A SWEDEHEART Study.

Journal of the American Heart Association·2026
Same author

Impact of Partial- to Full-Support Escalation With Microaxial Flow Pumps Prior to Durable Left Ventricular Assist Device Implantation.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026
Same author

Hypothermic oxygenated perfusion versus standard treatment of donor hearts in heart transplantation: extended follow-up of the NIHP2019 trial.

European heart journal·2026

関連する実験動画

Updated: Sep 9, 2025

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.4K

急性冠動脈症候群の冠動脈手術後のチカグレロールとアスピリンまたはアスピリン単独

Anders Jeppsson1,2, Stefan James3, Christian H Moller4

  • 1Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.

The New England journal of medicine
|September 1, 2025
PubMed
まとめ
この要約は機械生成です。

冠動脈バイパス移植 (CABG) の後のアスピリン治療にチカグレロルを追加しても,心血管不良は減少しませんでした. アスピリン単独投与と比較して,併用治療は大きな出血のリスクを高めました.

さらに関連する動画

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.6K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K

関連する実験動画

Last Updated: Sep 9, 2025

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.4K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.6K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K

科学分野:

  • 心臓病科
  • 心血管外科
  • 薬理学について

背景:

  • 急性冠動脈症候群の冠動脈バイパス移植 (CABG) 後の患者にとって抗血小板治療は極めて重要です.
  • この患者集団におけるアスピリンの治療に対するチカグレロの追加効果は不明である.

研究 の 目的:

  • アスピリン治療にチカグレロールを加えることで,アスピリン単独投与と比較して,CABG後の不良心血管結果が減少するかどうかを調べる.

主な方法:

  • 急性冠動脈症候群でCABGを受けた2201人の患者さんを対象とした,レジストリベースのオープン・ランダム化試験です.
  • 患者はチカグレロとアスピリン,またはアスピリン単独を1年間投与した.
  • 主なアウトカムは死亡,心筋梗塞,脳卒中,または再血管化でした.

主要な成果:

  • ティカグレロとアスピリンのグループ (4. 8%) とアスピリン単独のグループ (4. 6%) の間で主要な結果において有意な差異は認められなかった.
  • チカグレロールとアスピリンのグループでは,不良事象の発生率 (9. 1% 対 6. 4%) と大出血の発生率 (4. 9% 対 2. 0%) が高かった.

結論:

  • 急性冠動脈症候群のCABGを受けた患者では,アスピリン単独投与と比較して,チカグレロールとアスピリンの併用による主要な心血管疾患の発生率は低下しなかった.
  • 併用治療は重度の出血のリスクの増加と関連していました.